Atrial fibrillation: comorbidities, lifestyle, and patient factors

Eduard Shantsila, Eue Keun Choi, Deirdre A. Lane, Boyoung Joung, Gregory Y.H. Lip

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations

Abstract

Modern anticoagulation therapy has dramatically reduced the risk of stroke and systemic thromboembolism in people with atrial fibrillation (AF). However, AF still impairs quality of life, increases the risk of stroke and heart failure, and is linked to cognitive impairment. There is also a recognition of the residual risk of thromboembolic complications despite anticoagulation. Hence, AF management is evolving towards a more comprehensive understanding of risk factors predisposing to the development of this arrhythmia, its’ complications and interventions to mitigate the risk. This review summarises the recent advances in understanding of risk factors for incident AF and managing these risk factors. It includes a discussion of lifestyle, somatic, psychological, and socioeconomic risk factors. The available data call for a practice shift towards a more individualised approach considering an increasingly broader range of health and patient factors contributing to AF-related health burden. The review highlights the needs of people living with co-morbidities (especially with multimorbidity), polypharmacy and the role of the changing population demographics affecting the European region and globally.

Original languageEnglish
Article number100784
JournalThe Lancet Regional Health - Europe
Volume37
DOIs
StatePublished - Feb 2024

Bibliographical note

Publisher Copyright:
© 2023 The Author(s)

Keywords

  • Atrial fibrillation
  • Comorbidities
  • Lifestyle
  • Risk factors

Fingerprint

Dive into the research topics of 'Atrial fibrillation: comorbidities, lifestyle, and patient factors'. Together they form a unique fingerprint.

Cite this